The Effect of the COVID-19 Pandemic on Frailty in Liver Transplant Candidates
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05935800 |
Recruitment Status :
Active, not recruiting
First Posted : July 7, 2023
Last Update Posted : November 15, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Frailty Sarcopenia COVID-19 | Behavioral: COVID Patients who Underwent pre-transplant frailty assessment (PFA) at MDMC |
Study Type : | Observational |
Estimated Enrollment : | 208 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | The Effect of the COVID-19 Pandemic on Frailty in Liver Transplant Candidates |
Actual Study Start Date : | April 19, 2022 |
Estimated Primary Completion Date : | April 19, 2024 |
Estimated Study Completion Date : | April 19, 2024 |
- Behavioral: COVID Patients who Underwent pre-transplant frailty assessment (PFA) at MDMC
This is a single-center, retrospective study that uses de-identified, anonymized patient data. Data from 369 liver transplant candidates who underwent pre-transplant frailty assessments at the Liver Institute at Methodist Dallas from April 1, 2018 to February 28, 2022. The study data will be divided into cohorts: pre-COVID and COVID. Specifically, the pre-COVID period will consist of the dates between April 1st, 2018 and March 12, 2020, while the COVID period will consist of the dates between March 13, 2020 and February 28th, 2022.
- To determine the impact of the COVID-19 pandemic on the prevalence of sarcopenia [ Time Frame: 2 years ]To determine the impact of the COVID-19 pandemic on the prevalence of sarcopenia and frailty in patients undergoing liver transplant evaluation at Methodist Dallas Medical Center
- To determine the impact of the COVID-19 pandemic on the incidence of sarcopenia [ Time Frame: 2 years ]To determine the impact of the COVID-19 pandemic on the incidence of sarcopenia and frailty in patients undergoing liver transplant evaluation at Methodist Dallas Medical Center
- Changes in number of comorbidities between pre- and during/post-pandemic periods [ Time Frame: 1 year ]Changes in number of comorbidities between pre- and during/post-pandemic periods
- Changes in type of comorbidities between pre- and during/post-pandemic periods [ Time Frame: 1 year ]Changes in type of comorbidities between pre- and during/post-pandemic periods
- Changes in severity of comorbidities between pre- and during/post-pandemic periods [ Time Frame: 1 year ]Changes in severity of comorbidities between pre- and during/post-pandemic periods
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Age 18 years and older Underwent pre-transplant frailty assessment (PFA) at MDMC
Exclusion Criteria:
- Not a patient at Liver Institute at Methodist Dallas
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05935800
United States, Texas | |
Methodist Dallas Medical Center | |
Dallas, Texas, United States, 75203 |
Principal Investigator: | Parvez Mantry, MD | Methodist Health System |
Responsible Party: | Methodist Health System |
ClinicalTrials.gov Identifier: | NCT05935800 |
Other Study ID Numbers: |
012.HEP.2022.D |
First Posted: | July 7, 2023 Key Record Dates |
Last Update Posted: | November 15, 2023 |
Last Verified: | November 2023 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
COVID-19 Sarcopenia Frailty Pneumonia, Viral Pneumonia Respiratory Tract Infections Infections Virus Diseases Coronavirus Infections Coronaviridae Infections Nidovirales Infections |
RNA Virus Infections Lung Diseases Respiratory Tract Diseases Pathologic Processes Muscular Atrophy Neuromuscular Manifestations Neurologic Manifestations Nervous System Diseases Atrophy Pathological Conditions, Anatomical |